nk 121 profile

NK 121: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	56840902
MeSH ID	M0156042

Synonym
cis-1,1-cyclobutanedicarboxylato-(2r)-2-methyl-1,4-butanediammineplatinum(ii)
ci 973
platinum(ii), (cyclobutane-1,1-dicarboxylato)((r)-2-methyl-1,4-butanediammine)-, (z)-
(z)-(cyclobutane-1,1-dicarboxylato)((r)-2-methyl-1,4-butanediammine)platinum(ii)
1-cyclobutanedicarboxylato-2-methyl-1,4-butanediamine platinum(ii)
nk121
nk 121
unii-gz8i2x2fzk
DTXSID50891349
EX-A6277

Excerpt	Reference	Relevance
"The nephrotoxicity of three platinum-containing antitumor agents was compared at doses that approximate the LD10 (cisplatin) or the LD50 (CI-973, carboplatin) doses."	( Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Dominick, MA; Hoeschele, JD; Pegg, DG; Walsh, KM; Wolfgang, GH, 1994)	0.29

Excerpt	Reference	Relevance
" The seven agents combined with CI-973 were mitomycin C, cyclophosphamide, doxorubicin, vinblastine, etoposide, ifosfamide, and methotrexate."	( Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Elliott, WL; Howard, CT; Leopold, WR; Roberts, BJ, 1994)	0.29

Excerpt	Relevance	Reference
" Increases in exposure time of K562 cells to DWA2114R resulted in progressive shifting of the dose-response curve to the left, or more effective cell growth inhibition of the cells."	( Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Kobayashi, H; Miyachi, H; Ogawa, T; Takemura, Y, 1991)	0.28

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	8 (25.81)	18.7374
1990's	21 (67.74)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (6.45)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (17.14%)	5.53%
Reviews	3 (8.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (74.29%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	1.97	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ifosfamide [no description available]	1.98	1	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	1.98	1	0	mitomycin	alkylating agent; antineoplastic agent
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.6	1	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.67	3	0	elemental platinum; nickel group element atom; platinum group metal atom
etoposide [no description available]	1.98	1	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dw a 2114r [no description available]	7.74	12	2	platinum coordination entity; pyrrolidines	antineoplastic agent
bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) [no description available]	3.08	1	0
methotrexate [no description available]	1.98	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
carboplatin [no description available]	9.57	29	6
enloplatin enloplatin: structure given in first source	3.08	1	0
nedaplatin nedaplatin: structure given in first source	7.94	15	2

Condition	Relationship Strength	Studies	Trials
Airflow Obstruction, Chronic [description not available]	2.6	1	0
Chronic Bronchitis [description not available]	2.6	1	0
Asthma, Bronchial [description not available]	2.6	1	0
Centriacinar Emphysema [description not available]	2.6	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.6	1	0
Emphysema A pathological accumulation of air in tissues or organs.	2.6	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	2.6	1	0
Bronchitis, Chronic A subcategory of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. The disease is characterized by hypersecretion of mucus accompanied by a chronic (more than 3 months in 2 consecutive years) productive cough. Infectious agents are a major cause of chronic bronchitis.	2.6	1	0
HIV Coinfection [description not available]	2.6	1	0
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.6	1	0
Cancer of Colon [description not available]	1.98	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.98	1	0
B16 Melanoma [description not available]	1.98	1	0
EHS Tumor [description not available]	1.98	1	0
Animal Mammary Carcinoma [description not available]	1.98	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	1.98	1	0
Cancer of Stomach [description not available]	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.98	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	1.98	1	0
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Carcinoma, Non-Small Cell Lung [description not available]	5.72	2	2
Cancer of Lung [description not available]	6	3	2
Cancer of Ovary [description not available]	5.19	4	1
Cancer of Prostate [description not available]	4.28	1	1
Cancer of Testis [description not available]	4.28	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	5.72	2	2
Lung Neoplasms Tumors or cancer of the LUNG.	6	3	2
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	5.19	4	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	4.28	1	1
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	4.28	1	1
Benign Neoplasms [description not available]	5.75	4	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.75	4	2
Malignant Melanoma [description not available]	1.98	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.98	1	0
Recrudescence [description not available]	3.37	1	1
Acute Lymphoid Leukemia [description not available]	3.37	1	1
Blast Phase [description not available]	3.37	1	1
Leucocythaemia [description not available]	4.06	3	1
Granulocytic Leukemia, Chronic [description not available]	3.37	1	1
Acute Myelogenous Leukemia [description not available]	3.37	1	1
Acute Disease Disease having a short and relatively severe course.	3.37	1	1
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	3.37	1	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	4.06	3	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	3.37	1	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	3.37	1	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	3.37	1	1
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	3.37	1	1
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	3.37	1	1
Bone Cancer [description not available]	3.37	1	1
Breast Cancer [description not available]	3.37	1	1
Cancer of Liver [description not available]	3.37	1	1
Lymph Node Metastasis [description not available]	3.37	1	1
Cancer of Skin [description not available]	3.37	1	1
Neoplasms, Bone Marrow [description not available]	3.37	1	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.37	1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	3.37	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	3.37	1	1
Skin Neoplasms Tumors or cancer of the SKIN.	3.37	1	1
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	3.37	1	1
Bone Marrow Neoplasms Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.	3.37	1	1
Carcinoma, Oat Cell [description not available]	4.68	2	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	4.68	2	1
Acute Promyelocytic Leukemia [description not available]	1.98	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	1.98	1	0
Carcinoma, Epidermoid [description not available]	2.89	4	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.89	4	0
Experimental Leukemia [description not available]	1.97	1	0
Experimental Neoplasms [description not available]	2.38	2	0
Cancer of Esophagus [description not available]	1.97	1	0
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	1.97	1	0
Cancer of the Uterus [description not available]	1.97	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	1.97	1	0
Cancer of Pharynx [description not available]	1.97	1	0
Pharyngeal Neoplasms Tumors or cancer of the PHARYNX.	1.97	1	0
Sarcoma 180 An experimental sarcoma of mice.	1.97	1	0
Leukocytopenia [description not available]	2.38	2	0
Thrombopenia [description not available]	2.38	2	0
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	2.38	2	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.38	2	0
Mesonephroma A rare tumor of the female genital tract, most often the ovary, formerly considered to be derived from mesonephric rests. Two varieties are recognized: (1) clear cell carcinoma, so called because of its histologic resemblance to renal cell carcinoma, and now considered to be of muellerian duct derivation and (2) an embryonal tumor (called also ENDODERMAL SINUS TUMOR and yolk sac tumor), occurring chiefly in children. The latter variety may also arise in the testis. (Dorland, 27th ed)	1.97	1	0
Cancer of Head [description not available]	1.97	1	0
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1.97	1	0

nk 121

Description

Cross-References

Synonyms (10)

Research Excerpts

Toxicity

Compound-Compound Interactions

Dosage Studied

Research

Studies (31)

Market Indicators

Research Demand Index: 36.97

Study Types

nk 121

Description

Cross-References

Synonyms (10)

Research Excerpts

Toxicity

Compound-Compound Interactions

Dosage Studied

Research

Studies (31)

Market Indicators

Research Demand Index: 36.97

Study Types

Related Drugs (12)

Related Conditions (83)